PHC Group Releases Newly Revised Mid-Term Plan, the “Value Creation Plan,” Outlining Changes for FY2025 to Accelerate Growth by Advancing Value-Based Healthcare
16.11.2022 09:30:00 EET | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: Shoji Miyazaki, hereafter PHC Group) announces the release of its newly revised Mid-term Plan, the “Value Creation Plan”*1 for FY2022 to FY2025. The primary update in this plan is the introduction of new business growth areas that will enable PHC Group to advance value-based healthcare globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005183/en/
PHC Group’s Growth Areas (Graphic: Business Wire)
Our Value Creation Strategy Focuses on Realizing “Value-Based Healthcare”
Since the original Mid-term Plan was released in June 2021, PHC Group has initiated new commercial partnerships, expanded investments in our core business domains and completed its listing on the Tokyo Stock Exchange’s First Section (current Prime market) in October 2021. At the same time, increasing healthcare costs and disparities in access to healthcare, caused by issues like geographic location and income, continue to be critical challenges around the world. In light of these challenges, PHC Group has updated its global business strategy to focus on contributing to “Value-Based Healthcare,” a healthcare delivery model that seeks to maximize healthcare outcomes for patients based on their individual needs, which can lead to better care as well as improved cost-effectiveness.
Specifically, PHC Group will seek to strengthen its three core business domains while leveraging synergies among those businesses to target three new growth areas:
Strategy on Foundation (Core Business Domains)
- Diabetes Management: PHC Group will expand new business opportunities for blood glucose monitoring systems (BGM) in emerging markets and enhance growth business such as continuous glucose monitoring system (CGM).
- Healthcare Solutions: The Medicom (healthcare IT) business in Japan will seek to capitalize on demand from the shift to cloud-based electronic medical record (EMR) systems and Japanese government-led policies. The LSI Medience (clinical testing services and diagnostic reagents) business will enhance cancer and genetic testing and boost clinical trials and point-of-care testing (POCT) businesses outside of Japan.
- Diagnostics & Life Sciences: The PHCbi (biomedical) business will develop new products with energy-saving performance and internet of things (IoT) technology, and also optimize its global operations in development and manufacturing. The Epredia (anatomical pathology) business will seek to increase its market share by upgrading product quality and tapping into sales channels by region and segment used by PHC Group Business.
Strategy for Growth
- Personalized Testing and Diagnostic Solutions: The diabetes management business, including Ascensia and PHC IVD, will promote sales of its innovative CGM and develop POCT technologies.
- Digital Health Solutions: Medicom and LSI Medience will integrate their healthcare management businesses including annual health check programs to advance health support including preventive medicine for individuals. They will advance solutions that assist the workflow for healthcare professionals such as administrative support services efficiently managed by AI. To contribute to reducing healthcare costs and enhancing treatments, PHC Group will work to integrate and analyze health data.
- Advanced Therapy Development Solutions: The Epredia and PHCbi businesses will leverage one another’s customer networks in pharmaceutical companies to expand sales globally for both brands. Expanded product portfolios will include new equipment for cell metabolism analysis and anatomical pathology, and high-quality, high-speed models for diagnostics using AI will be developed for hospitals.
Revised Financial Targets
Through this Value Creation Plan, PHC Group is targeting 420 bn/JPY in revenue and 56 bn/JPY in operating profit:
|
FY2021 Actual |
FY2025 Target*2 |
CAGR | 2021-2025 |
|
| Revenue | 340.5bn | 420bn |
+5.4% |
| Operating Profit | 8.2bn | 56bn |
+62% |
| (Margin) |
(2%) |
(13%) |
20% if impairment |
| Impairment of | is not included | ||
| 18.4bn/JPY of Epredia | |||
| business included | |||
| Cash-based | 24.8bn | 49bn |
+19% |
| net income | |||
| EBITDA | 57.7bn | 87bn |
+11% |
| Adjusted EBITDA | 71.9bn | 87bn |
+4.9% |
| Reference | |||
| Assumed Exchange Rate | |||
|
$ |
112JPY | 130JPY | |
|
€ |
130JPY | 132JPY | |
With this combination of foundational business and new growth areas, PHC Group’s newly revised Value Creation Plan will help the company advance its corporate mission of “contributing to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people.”
*1 Website on our “Value Creation Plan”: www.phchd.com/global/about/vcp
*2 Based on current business portfolio
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO Prime 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries.
www.phchd.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005183/en/
Contact information
Media Contact:
Julia Cottrill
Hiroko Arai
Investor Relations & Corporate Communications Group
PHC Holdings Corporation
TEL: +81-3-6778-5311
Email:
phc-pr@gg.phchd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 14:12:00 EEST | Press release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom